insights from industryDr Chelsea PrattBiopharma Segment Marketing ManagerBio-Rad Laboratories In this interview, NewsMedical speaks to Dr Chelsea Pratt about Accurately quantifying AAV capsids ...
Quantification of empty and full adeno-associated virus (AAV) capsids is crucial for maximizing viral vectors used in gene therapy. The launch of the Vericheck ddPCR Empty-Full Capsid Kit expands this ...
The kits offer customers the ability to rapidly perform high-throughput in vitro, ex vivo, and in vivo screening to identify optimal AAV Capsids that are suitable for tissue-specific delivery in gene ...
Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...
WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) announced today that the Company presented preclinical data from its novel adeno-associated virus (AAV) gene therapy ...
At a median 13 years after a single infusion of AAV-mediated gene therapy, factor IX expression remained stable in 10 patients with severe hemophilia B. The median annualized bleeding rate decreased ...
The MarketWatch News Department was not involved in the creation of this content. -- Partnership reinforces PackGene's leadership in AAV solutions and rapid vector serotype screening -- Customizable ...
HOUSTON and SYDNEY, Aug. 26, 2025 /PRNewswire/ -- PackGene Biotech, a global contract research organization (CRO) and contract development and manufacturing organization (CDMO) leader in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback